Key Highlights: Implications: Poviztra’s new MASH label lets Emcure plug innovator semaglutide directly into India’s emerging fatty liver treatment market, riding on ESSENCE data (63% stea...
Key Highlights: Implications: Emcure’s move to take Gennova to 100% ownership and fold it under the “One Emcure” framework tightens control over a strategically important biologi...
Key Highlights: Implications: The slump sale of Gennova’s small mRNA unit to Immunoscript for ₹139.5 crore effectively exits Emcure from a non-core, low-contribution bu...
Key Highlights: Implications: Mankind Pharma’s AI-led drug discovery partnership with Denovo Sciences strengthens its innovation agenda and adds another serious player to India’s eme...
Key Highlights: Implications: Pivot Path’s majority sale to an Ascent-led consortium effectively spins it out as an independent, PE-backed specialist, which should accelerate its growth in...
Key Highlights: Implications: Zaynich’s approval gives Wockhardt a home-grown differentiated anti‑infective positioned squarely at India’s metallo‑β‑lactamase (MBL) and XDR Gram‑...
Key Highlights: Implications: Align’s new Hyderabad plant is a big capacity and margin move, not just a footprint expansion. It should make the company more resilient on supply, ...
Key Highlights: Implications: Triple Hair is turning TH07 into a genuinely global late‑stage asset in male pattern hair loss by running synchronized Phase III trials in Canada and In...
Key Highlights: Implications: AstraZeneca India is partnering with Telangana to embed Qure.ai’s chest X‑ray AI into routine workflows at about 20 public facilities, turning basic radiography into a lu...
Clinical Trials in India: Growth, Ethics & Global Positioning Recent Industry Context Clinical trials have always been a crucial pillar of healthcare innovation, acting as the bridge b...
